^
    Back
    Association details:
    Biomarker:HER-2 mutation
    Cancer:Colorectal Cancer
    Drug:Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Title:

    Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer

    Excerpt:
    AstraZeneca and Daiichi Sankyo’s (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    Trastuzumab Deruxtecan DESTINY for Some Cancers

    Published date:
    06/02/2020
    Excerpt:
    It also elicited high response rates in phase II trials of HER2-mutant non-small cell lung cancer and HER2-positive colorectal cancer.
    DOI:
    10.1158/2159-8290.CD-ND2020-011
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

    Published date:
    03/25/2020
    Excerpt:
    In the HER2-expressing or HER2-mutant colorectal cancer subgroup, 5.0% (1/20) of patients had a confirmed objective response. A total of 85.0% of patients with colorectal cancer (17/20) had a PFS event, and the median PFS was 4.0 (95% CI, 2.7–5.6) months (Fig. 2). Among 9 patients with HER2 IHC 3+ colorectal cancer, the confirmed ORR was 11.1% (1/9) and the confirmed DCR was 100% (9/9).
    DOI:
    10.1158/2159-8290.CD-19-1014